<?php die("Access Denied"); ?>#x#a:5:{s:4:"body";s:1475:"

<div class="item-page clearfix">


<!-- Article -->
<article itemscope itemtype="http://schema.org/Article">
	<meta itemprop="inLanguage" content="en-GB" />


<!-- Aside -->
<!-- //Aside -->




	

	

	
	
	<section class="article-content clearfix" itemprop="articleBody">
		<p>Persivia enables clinicians to monitor patients on high-risk anticoagulation medications in order to maximize safety and efficacy of their anticoagulation therapy, such as Heparin and Coumadin.</p>
<h4>Persivia’s Anticoagulation Management Solution Includes:</h4>
<ul>
<li>Patient Safety: Alerts on adverse drug reaction and adverse event avoidance according to the <a href="http://www.jointcommission.org/standards_information/npsgs.aspx">Joint Commissions’ National Patient Safety Goals</a> to reduce patient adverse events associated with anticoagulation treatment</li>
<li>Dashboard of information: Review anticoagulant orders, associated lab results, and other flagged information</li>
<li>Patient Surveillance: Monitor therapeutic levels and identify potential adverse events and hospital-acquired conditions</li>
</ul>
<h4>Persivia is the Anticoagulation Management Solution to:</h4>
<ul>
<li>Provide early warning of adverse events</li>
<li>Monitor therapeutic levels</li>
<li>Reduce adverse events</li>
<li>Push real-time information of associated lab results</li>
</ul>	</section>
	
  <!-- footer -->
    <!-- //footer -->

	
	
	
</article>
<!-- //Article -->


</div>";s:4:"head";a:11:{s:5:"title";s:19:"Persivia - Persivia";s:11:"description";N;s:4:"link";s:0:"";s:8:"metaTags";a:2:{s:10:"http-equiv";a:1:{s:12:"content-type";s:24:"text/html; charset=utf-8";}s:8:"standard";a:2:{s:8:"keywords";s:126:"clinical decision support medication management infection control population health management quality healthcare chronic care";s:6:"rights";N;}}s:5:"links";a:1:{s:60:"http://persivia.com/component/content/?id=237&amp;Itemid=839";a:3:{s:8:"relation";s:9:"canonical";s:7:"relType";s:3:"rel";s:7:"attribs";a:0:{}}}s:11:"styleSheets";a:1:{s:53:"/plugins/content/jadisqus_debate_echo/asset/style.css";a:3:{s:4:"mime";s:8:"text/css";s:5:"media";N;s:7:"attribs";a:0:{}}}s:5:"style";a:0:{}s:7:"scripts";a:8:{s:33:"/media/system/js/mootools-core.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:24:"/media/system/js/core.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:33:"/media/system/js/mootools-more.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:27:"/media/jui/js/jquery.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:34:"/media/jui/js/jquery-noconflict.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:35:"/media/jui/js/jquery-migrate.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:27:"/media/system/js/caption.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:30:"/media/jui/js/bootstrap.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}}s:6:"script";a:1:{s:15:"text/javascript";s:576:"
var disqus_shortname = 'jademo-light';
var disqus_config = function(){
	this.language = 'en';
};
window.addEvent('load', function(){
	(function () {
	  var s = document.createElement('script'); s.async = true;
	  s.src = '//jademo-light.disqus.com/count.js';
	  (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(s);
	}());
});
jQuery(window).on('load',  function() {
				new JCaption('img.caption');
			});jQuery(document).ready(function(){
	jQuery('.hasTooltip').tooltip({"html": true,"container": "body"});
});";}s:6:"custom";a:0:{}s:10:"scriptText";a:0:{}}s:13:"mime_encoding";s:9:"text/html";s:7:"pathway";a:0:{}s:6:"module";a:0:{}}